Syneos Health, Inc.

NasdaqGS:SYNH Voorraadrapport

Marktkapitalisatie: US$4.5b

Syneos Health Beheer

Beheer criteriumcontroles 1/4

Syneos Health's CEO is Michelle Keefe, appointed in Apr 2022, has a tenure of 1.42 years. total yearly compensation is $8.89M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $1.53M. The average tenure of the management team and the board of directors is 2.7 years and 2.3 years respectively.

Belangrijke informatie

Michelle Keefe

Algemeen directeur

US$8.9m

Totale compensatie

Percentage CEO-salaris9.7%
Dienstverband CEO1.4yrs
Eigendom CEO0.03%
Management gemiddelde ambtstermijn2.7yrs
Gemiddelde ambtstermijn bestuur2.3yrs

Recente managementupdates

Recent updates

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 29
Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Mar 10
Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Feb 20
Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Dec 20
Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

Nov 28
Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Nov 01
Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos, Datavant expand partnership on data analytics for clinical trials

Oct 11

Syneos Health falls 13% after update on outlook

Sep 13

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Sep 08
When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Aug 22
Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health Q2 2022 Earnings Preview

Aug 01

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Jul 19
With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Jul 15

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18
Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03
Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19
We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08
Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05
Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18
Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03
Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04
With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03
Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Analyse CEO-vergoeding

Hoe is Michelle Keefe's beloning veranderd ten opzichte van Syneos Health's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2023n/an/a

US$71m

Mar 31 2023n/an/a

US$148m

Dec 31 2022US$9mUS$862k

US$266m

Sep 30 2022n/an/a

US$287m

Jun 30 2022n/an/a

US$278m

Mar 31 2022n/an/a

US$242m

Dec 31 2021US$2mUS$567k

US$235m

Sep 30 2021n/an/a

US$251m

Jun 30 2021n/an/a

US$236m

Mar 31 2021n/an/a

US$198m

Dec 31 2020US$2mUS$522k

US$193m

Sep 30 2020n/an/a

US$192m

Jun 30 2020n/an/a

US$187m

Mar 31 2020n/an/a

US$195m

Dec 31 2019US$2mUS$550k

US$131m

Compensatie versus markt: Michelle's total compensation ($USD8.89M) is above average for companies of similar size in the US market ($USD6.59M).

Compensatie versus inkomsten: Michelle's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Michelle Keefe (56 yo)

1.4yrs

Tenure

US$8,889,996

Compensatie

Ms. Michelle Keefe serves as Chief Executive Officer at Syneos Health, Inc since April 29, 2022 and serves as its Director since 2022. She served as President of Medical Affairs and Commercial Solutions fo...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Michelle Keefe
CEO & Director1.4yrsUS$8.89m0.034%
$ 1.5m
Michael Brooks
Chief Operating Officer1.4yrsUS$6.04m0.018%
$ 810.0k
Jonathan Olefson
General Counsel & Corporate Secretary4.8yrsUS$3.52m0.014%
$ 617.4k
Christian Tucat
Chief Business Officer5yrsUS$2.62m0.011%
$ 502.0k
Jason Meggs
Consultantless than a yearUS$3.19m0.039%
$ 1.8m
Michael Bonello
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Donna Kralowetz
Senior VP of Finance & Chief Accounting Officer2.7yrsgeen gegevens0.0029%
$ 130.6k
Baba Shetty
President of Technology & Data Solutions1.4yrsgeen gegevensgeen gegevens
Judith Ng-Cashin
Chief Scientific Officer7.5yrsgeen gegevensgeen gegevens
Larry Pickett
Chief Information & Digital Officer2.8yrsgeen gegevensgeen gegevens
Ronnie Speight
Senior Vice President of Investor Relationsno datageen gegevensgeen gegevens
Kristen Spensieri
Global Head of Corporate Communications & Marketing6.1yrsgeen gegevensgeen gegevens

2.7yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: SYNH's management team is considered experienced (2.7 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Michelle Keefe
CEO & Director1.7yrsUS$8.89m0.034%
$ 1.5m
Kenneth Meyers
Independent Director6.9yrsUS$370.77k0.019%
$ 865.7k
William Klitgaard
Independent Directorless than a yearUS$182.56k0%
$ 0
Matthew Monaghan
Independent Director6.9yrsUS$322.77k0.019%
$ 850.1k
Alfonso Zulueta
Independent Director1.7yrsUS$351.39k0.0034%
$ 150.2k
John Dineen
Independent Chairman4.8yrsUS$483.27k0.022%
$ 972.7k
David Wilkes
Independent Director2.3yrsUS$308.52k0.0048%
$ 213.5k
Bernadette Connaughton
Independent Director3.8yrsUS$307.77k0.0096%
$ 426.2k
Barbara Bodem
Independent Director1.7yrsUS$369.53k0.0034%
$ 151.6k

2.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: SYNH's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.